181 related articles for article (PubMed ID: 19093871)
1. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.
Xia CF; Boado RJ; Pardridge WM
Mol Pharm; 2009; 6(3):747-51. PubMed ID: 19093871
[TBL] [Abstract][Full Text] [Related]
2. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology.
Xia CF; Zhang Y; Zhang Y; Boado RJ; Pardridge WM
Pharm Res; 2007 Dec; 24(12):2309-16. PubMed ID: 17926121
[TBL] [Abstract][Full Text] [Related]
3. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery.
Jain A; Barve A; Zhao Z; Jin W; Cheng K
Mol Pharm; 2017 May; 14(5):1517-1527. PubMed ID: 28026957
[TBL] [Abstract][Full Text] [Related]
5. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
6. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Yoshikawa T; Pardridge WM
J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704
[TBL] [Abstract][Full Text] [Related]
7. shRNA and siRNA delivery to the brain.
Pardridge WM
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):141-52. PubMed ID: 17434235
[TBL] [Abstract][Full Text] [Related]
8. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
9. [Interaction of triiodothyronine-biotin conjugate with binding proteins in immunoassay systems].
Navakouskiĭ MJ; Vashkevich II; Sviridov OV
Bioorg Khim; 2012; 38(4):449-57. PubMed ID: 23189559
[TBL] [Abstract][Full Text] [Related]
10. Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
Bioconjug Chem; 2012 Jun; 23(6):1318-21. PubMed ID: 22624578
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Foulon CF; Bigner DD; Zalutsky MR
Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
[TBL] [Abstract][Full Text] [Related]
12. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor.
Coloma MJ; Lee HJ; Kurihara A; Landaw EM; Boado RJ; Morrison SL; Pardridge WM
Pharm Res; 2000 Mar; 17(3):266-74. PubMed ID: 10801214
[TBL] [Abstract][Full Text] [Related]
13. A monoclonal antibody to avidin dissociates quaternary structure and curtails biotin binding to avidin and streptavidin.
Subramanian N; Subramanian S; Karande AA; Adiga PR
Arch Biochem Biophys; 1997 Aug; 344(2):281-8. PubMed ID: 9264540
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
15. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
16. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
[TBL] [Abstract][Full Text] [Related]
17. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
Boado RJ
Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
[TBL] [Abstract][Full Text] [Related]
18. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody.
Dou S; Virostko J; Greiner DL; Powers AC; Liu G
Mol Pharm; 2015 Aug; 12(8):3097-103. PubMed ID: 26103429
[TBL] [Abstract][Full Text] [Related]
20. Quantitative determination of staphylococcal enterotoxin A by an enzyme-linked immunosorbent assay using a combination of polyclonal and monoclonal antibodies and biotin-streptavidin interaction.
Edwin C
J Clin Microbiol; 1989 Jul; 27(7):1496-501. PubMed ID: 2768439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
